News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Pradaxa Capsules of Boehringer lngelheim
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
Subscribe To Our Newsletter & Stay Updated
